NADiA ProsVue Prostate-specific Antigen Slope, CAPRA-S, and Prostate Cancer–specific Survival After Radical Prostatectomy - 26/11/14
, Mark J. Sarno c, Jonathan E. McDermed d, Melissa T. Triebell d, Mark A. Reynolds eAbstract |
Objective |
To assess whether NADiA ProsVue prostate-specific antigen slope, a prognostic biomarker for identifying men at a reduced risk of clinically recurrent prostate cancer after radical prostatectomy, is prognostic for prostate cancer–specific mortality (PCSM) and other outcomes.
Materials and Methods |
We examined long-term outcome in the cohort of 304 men selected for the ProsVue 510(k) clinical trial. We assessed the prognostic value of a ProsVue result ≤2.0 pg/mL/mo and pathologic risk stratified by the Cancer of the Prostate Risk Assessment Postsurgical nomogram for a reduced risk of prostate cancer–specific survival. We also assessed its value for predicting clinical outcome in men given salvage treatment for biochemical recurrence. Efficacy was assessed using univariate and multivariate Cox regression and the Kaplan-Meier analyses.
Results |
Median (interquartile range) overall survival for the groups of men with a ProsVue slope result ≤2.0 and >2.0 pg/mL/mo were 11.0 (9.4-12.9) and 9.2 (4.9-11.6) years, respectively. The ProsVue univariate hazard ratio (95% confidence interval) for PCSM was 20.6 (6.8-62.7), with P <.0001 for a ProsVue result >2.0 pg/mL/mo vs a result ≤2.0 pg/mL/mo. The multivariate hazard ratio of ProsVue adjusted by Cancer of the Prostate Risk Assessment Postsurgical nomogram remained significant (16.7 [4.7-58.6]; P <.0001). The inverse of the hazard ratio translates to a 94.0% risk reduction for PCSM for men with a ProsVue result ≤2.0 pg/mL/mo. Salvage treatment for biochemical recurrence did not significantly reduce the hazard of clinical recurrence or PCSM; however, this is based on only 18 events.
Conclusion |
A NADiA ProsVue slope result ≤2.0 pg/mL/mo was prognostic for a reduced risk of PCSM in men after radical prostatectomy.
Le texte complet de cet article est disponible en PDF.Plan
| Financial Disclosure: Mark J. Sarno is a paid, independent consultant to IRIS. Jonathan E. McDermed, Melissa T. Triebell, and Mark A. Reynolds are employees of sponsor IRIS Personalized Medicine. The remaining author declares that he has no relevant financial interests. |
|
| Funding support: Patient samples from the University of Washington were collected in part using funding from the National Institutes of Health NW Prostate Cancer SPORE (grant CA-097186) and National Institutes of Health PO1 (grant CA-085859). Funding support to Memorial Sloan-Kettering Cancer Center was provided in part from the National Cancer Institute (grant P50-CA92629); Sidney Kimmel Center for Prostate and Urologic Cancers; David H. Koch through the Prostate Cancer Foundation. Salary support for Judd W. Moul is partially funded by The Committee for Urologic Research and Education and the James H Semans M.D. Endowed Professorship at Duke University. |
Vol 84 - N° 6
P. 1427-1433 - décembre 2014 Retour au numéro
Article précédent
- Outcomes After Urothelial Recurrence in Bladder Cancer Patients Undergoing Radical Cystectomy
- Anirban P. Mitra, Mehrdad Alemozaffar, Brianna N. Harris, Anne K. Schuckman, Eila C. Skinner, Siamak Daneshmand
- Editorial Comment
- Todd M. Morgan, Felix Y. Feng
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?